Connect with us
DAPA Banner

Crypto World

Anthropic Trust Adds Novartis CEO to Board

Published

on

Anthropic Trust Adds Novartis CEO to Board

Anthropic Trust has appointed Vas Narasimhan, CEO of Novartis, to Anthropic’s board of directors, making him the first pharmaceutical industry executive to join the AI lab’s governing body and tipping Trust-appointed directors to a board majority for the first time.

Summary

  • Narasimhan was appointed on April 14 by the Anthropic Long-Term Benefit Trust, the independent body whose members hold no equity in Anthropic and exist solely to elect board directors aligned with the company’s public benefit mission.
  • With his appointment, Trust-selected directors now hold a majority of seats on the seven-person board, a governance threshold written into Anthropic’s founding documents but not crossed until now.
  • The appointment lands as Anthropic weighs an IPO at a reported $380 billion valuation and deepens its push into healthcare through Claude for Life Sciences and Claude for Healthcare.

Anthropic Trust appointed Vas Narasimhan, CEO of Novartis, to Anthropic’s board of directors on April 14, 2026. With his arrival, directors chosen by the Long-Term Benefit Trust now hold a majority of the seven-person board, crossing a structural governance threshold written into Anthropic’s founding charter but never previously exercised.

Narasimhan is a physician-scientist who has overseen the development and regulatory approval of more than 35 novel medicines and vaccines at Novartis, one of the world’s largest innovative medicines companies. He joins Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell.

Advertisement

The Anthropic Long-Term Benefit Trust is a separate legal body that holds a special class of Anthropic stock whose only purpose is electing board directors. Its three trustees hold no equity in Anthropic, draw no salary from it, and are selected by each other rather than by shareholders. The current trustees are Buddy Shah of the Clinton Health Access Initiative, Richard Fontaine of the Center for a New American Security, and Mariano-Florentino Cuéllar of the Carnegie Endowment for International Peace.

The Trust’s explicit mandate is to ensure Anthropic balances financial success with its public benefit mission of developing AI responsibly. Trust Chair Neil “Buddy” Shah said the group specifically sought someone who had stewarded breakthrough science responsibly in a highly regulated setting.

Narasimhan is the third director the Trust has placed on the board, joining existing Trust appointees Jay Kreps and Reed Hastings. Together they now constitute a majority, a shift that gives the Trust’s safety and public benefit mandate structural weight in board decisions for the first time.

Advertisement

The Healthcare Signal

The appointment is not random timing. Anthropic launched Claude for Life Sciences in October 2025 and Claude for Healthcare in January 2026, adding HIPAA-ready infrastructure and tools aimed at clinical, regulatory, and scientific workflows. The company has partnerships with Eli Lilly, Novo Nordisk, and Genmab to explore how AI can compress drug development timelines.

Bringing in a sitting pharma CEO with two decades of regulated-industry experience gives Anthropic direct expertise on the board as Claude’s deployment in clinical and research environments scales. Narasimhan said on LinkedIn that “speed alone isn’t the goal” in healthcare AI, and that “what matters just as much is how these tools are built, governed, and ultimately applied in the real world.”

Daniela Amodei said Narasimhan “brings something rare to our board. He’s overseen the development and approval of more than 35 novel medicines for the benefit of patients around the world in one of the most regulated industries. Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic.”

IPO Context

Anthropic’s annualized revenue has surpassed $30 billion, up from $9 billion at end-2025, as demand for Claude models accelerates across enterprise. The company is reportedly weighing an IPO at a $380 billion valuation, and board composition is increasingly scrutinized by investors ahead of a public listing.

Advertisement

The addition of a pharma CEO to a Trust-majority board signals that Anthropic wants its safety-first positioning to translate into credibility with regulated-sector institutional buyers, not just a PR narrative. For a company preparing to access public markets, the governance architecture now matches the story.

Source link

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Crypto World

Flow Capital to Tokenize $150M Private Credit Fund on Blockchain: Report

Published

on

Flow Capital to Tokenize $150M Private Credit Fund on Blockchain: Report

Flow Capital Partners is planning to tokenize its private credit fund through Singapore-based DigiFT, Bloomberg reported Friday, as the Hong Kong credit manager looks to tap blockchain-based distribution for its next capital raise.

According to the report, Flow Capital plans to bring its $150 million private credit fund on the blockchain through Singapore-based tokenization platform DigiFT by the end of April, seeking to raise an additional $30 million in tokenized shares by the end of 2026, Jacky Tian, chief investment officer of Flow Capital, said.

The $30 million raise is part of the company’s plans to expand the size of the fund to $250 million with a target net return of 12%. The fund launched in mid 2025, with $125 million in seed capital, according to the company. Cointelegraph has approached Flow Capital and DigiFT for comment.

The move adds to a growing push to use tokenization as a distribution channel for traditional credit products.

Advertisement

Some of the largest TradFi companies have announced similar tokenization initiatives, including asset manager BlackRock, which launched its BlackRock USD Institutional Digital Liquidity Fund (BUIDL), a tokenized treasury fund on Ethereum, in March 2024. Investment banking giant JPMorgan also launched its tokenized money-market fund, My OnChain Net Yield Fund (MONY), on Ethereum in December 2025.

However, industry leaders have raised misconceptions tied to the liquidity of tokenized assets.

Related: Gold, silver and oil drive 65,000% jump in commodity perpetuals

Executives warn tokenization isn’t liquidity

Oya Celiktemur, Ondo Finance sales director for Europe, said tokenization doesn’t magically make hard-to-trade assets liquid.

Advertisement

“I think there’s still this idea that tokenizing something illiquid will somehow magically make it a liquid asset, which is just not true,” said Celiktemur, speaking during a panel discussion at Paris Blockchain Week 2026.

Francesco Ranieri Fabracci, head of tokenization expansion at Tether, made a similar point, arguing that tokenizing an asset won’t make it liquid, but added that some instruments, including bonds, money market funds and stablecoin, will likely see consistent liquidity on blockchain rails.

Tokenized RWA value, all-time chart. Source: RWA.XYZ

The total value of tokenized assets rose 9.6% during the past 30 days to $29.9 billion on Friday, data from RWA.xyz shows.

Tokenized US treasury debt was the largest sector with $13.7 billion in value, followed by commodities with $5.4 billion and asset-backed credit with $3.2 billion.

Advertisement

Magazine: Can Robinhood or Kraken’s tokenized stocks ever be truly decentralized?